

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

UPDATE ON CIVIL PROCEEDINGS

The announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated January 24, 2025 (the “**Previous Announcement**”) in respect of the civil ruling (the “**Civil Ruling**”) issued by the Qingdao Intermediate People’s Court (青島市中級人民法院), which, among other measures, had preserved certain bank accounts and/or equivalent assets of our Group. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Previous Announcement.

After extensive discussions addressing each party’s interests and concerns, the Group and Qingdao Hainuo have agreed to unfreeze the bank accounts of one of our subsidiaries, which serves as the commercial operation company of 恩維達®. As of the date of this announcement, the preservation order on such bank accounts had been lifted.

As disclosed in the Previous Announcement, the Group had applied for the court for a reconsideration to revoke the Civil Ruling. A hearing was held on February 5, 2025, whereby the relevant materials were submitted to the court. Although the time limit set by law for the rendering of a decision had passed, we have made efforts to communicate with the court, yet we still have not received further civil rulings from the court.

Both the Group and Qingdao Hainuo have been actively engaging in ongoing discussions to explore reasonable solutions. Both parties have demonstrated a commitment to seeking solutions that respect their respective rights and obligations while ensuring compliance with legal and regulatory requirements.

Based on the Group’s ongoing monitoring and assessment of its cash flow, the Board is of the view that the Civil Ruling will not have a material impact on the commercialization of ENWEIDA, 恩維達®. However, the Board acknowledges that the Civil Ruling may have some adverse effects on the Group’s operations and research and development activities, but the accounts for receiving the Company’s public offering proceeds were not affected, and the Company’s own funds can maintain the normal operation of the Company’s activities.

The Board will continue to closely monitor and assess the implications of the matters outlined above on the Group's overall operations. The Company will issue further announcements to update shareholders and the public as required under the Listing Rules.

Shareholders and public investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, February 17, 2025

As at the date of this announcement, the Board comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.